All In Biotech

Drug Trial Radar · NCT05490017

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

SYNERGY-1: A Phase 1 First-in-human, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Dec 30, 2020

Primary completion

May 4, 2022

Study completion Sep 2, 2022

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of KP104 and Part 2, multiple ascending dose (MAD).

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • KP104Drug

    Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

  • PlaceboDrug

    Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants reporting Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 85
  2. Number of participants reporting Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Up to Day 85
  3. Number of participants with Dose-limiting toxicities (DLT)Time frame: Up to Day 85
  4. Number of participants reporting AEs of Special interests (AESIs)Time frame: Up to Day 85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.